(Q53592726)

16 May 2018

title

Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. (English)

1 reference

16 May 2018

0 references

1 reference

Nomura S

1

1 reference

16 May 2018

Inami N

2

1 reference

16 May 2018

Kimura Y

3

1 reference

16 May 2018

Omoto S

4

1 reference

16 May 2018

Shouzu A

5

1 reference

16 May 2018

Nishikawa M

6

1 reference

16 May 2018

Iwasaka T

7

1 reference

16 May 2018

publication date

19 October 2006

1 reference

16 May 2018

Journal of Human Hypertension

published in

1 reference

16 May 2018

volume

21

1 reference

16 May 2018

issue

1

1 reference

16 May 2018

page(s)

38-44

1 reference

16 May 2018

Function and clinical significance of platelet-derived microparticles

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Increased levels of platelet-derived microparticles in patients with diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Procoagulant and profibrinolytic activities of cryopreserved human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Benidipine improves oxidized LDL-dependent monocyte and endothelial dysfunction in hypertensive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Adiponectin stimulates production of nitric oxide in vascular endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Globular adiponectin upregulates nitric oxide production in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Microalbuminuria and coronary heart disease in NIDDM: an incidence study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Long-term comparison between captopril and nifedipine in the progression of renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Effects of a novel calcium antagonist, benidipine hydrochloride, on platelet responsiveness to mental stress in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Insulin decreases human adiponectin plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

Diabetes mellitus as a hypercoagulable state: its relationship with fibrin fragments and vascular damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

7 January 2021

Platelet function in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

7 January 2021

Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

7 January 2021

Detection of monocyte-derived microparticles in patients with Type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

7 January 2021

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

7 January 2021

Diversity in the Renal Hemodynamic Effects of Dihydropyridine Calcium Blockers in Spontaneously Hypertensive Rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

7 January 2021

Shanghai trial of nifedipine in the elderly (STONE)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

7 January 2021

In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with alpha-tocopherol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

7 January 2021

Isradipine improves platelet function in hypertensives

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

7 January 2021

A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002100

7 January 2021

Identifiers

DOI

10.1038/SJ.JHH.1002100

1 reference

16 May 2018

1 reference

16 May 2018